The Role of Gut Microbiota Augmentation in Managing Non-alcoholic Fatty Liver Disease: an In-depth Umbrella Review of Meta-analyses with Grade Assessment

Overview

Journal Ann Med Surg (Lond)

Publisher Wolters Kluwer

Specialty Medical Education

Date 2024 Aug 9

PMID 39118769

Authors

Gautam Maddineni

Sri J Obulareddy

Ruchir D Paladiya

Rohan R Korsapati

Shika Jain

Herby Jeanty

Fnu Vikash

Nayanika C Tummala

Samatha Shetty

Arezoo Ghazalgoo

Abinash Mahapatro

Viswanadh Polana

Dhruvan Patel

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Currently, there are no authorized medications specifically for non-alcoholic fatty liver disease (NAFLD) treatment. Studies indicate that changes in gut microbiota can disturb intestinal balance and impair the immune system and metabolism, thereby elevating the risk of developing and exacerbating NAFLD. Despite some debate, the potential benefits of microbial therapies in managing NAFLD have been shown.

Methods: A systematic search was undertaken to identify meta-analyses of randomized controlled trials that explored the effects of microbial therapy on the NAFLD population. The goal was to synthesize the existing evidence-based knowledge in this field.

Results: The results revealed that probiotics played a significant role in various aspects, including a reduction in liver stiffness (MD: -0.38, 95% CI: [-0.49, -0.26]), hepatic steatosis (OR: 4.87, 95% CI: [1.85, 12.79]), decrease in body mass index (MD: -1.46, 95% CI: [-2.43, -0.48]), diminished waist circumference (MD: -1.81, 95% CI: [-3.18, -0.43]), lowered alanine aminotransferase levels (MD: -13.40, 95% CI: [-17.02, -9.77]), decreased aspartate aminotransferase levels (MD: -13.54, 95% CI: [-17.85, -9.22]), lowered total cholesterol levels (MD: -15.38, 95% CI: [-26.49, -4.26]), decreased fasting plasma glucose levels (MD: -4.98, 95% CI: [-9.94, -0.01]), reduced fasting insulin (MD: -1.32, 95% CI: [-2.42, -0.21]), and a decline in homeostatic model assessment of insulin resistance (MD: -0.42, 95% CI: [-0.72, -0.11]) (<0.05).

Conclusion: Overall, the results demonstrated that gut microbiota interventions could ameliorate a wide range of indicators including glycemic profile, dyslipidemia, anthropometric indices, and liver injury, allowing them to be considered a promising treatment strategy.

References

Cani P, Neyrinck A, Fava F, Knauf C, Burcelin R, Tuohy K . Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007; 50(11):2374-83. DOI: 10.1007/s00125-007-0791-0. View

Johnson-Henry K, Donato K, Shen-Tu G, Gordanpour M, Sherman P . Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function. Infect Immun. 2008; 76(4):1340-8. PMC: 2292865. DOI: 10.1128/IAI.00778-07. View

Zhang M, Wang C, Wang C, Zhao H, Zhao C, Chen Y . Enhanced AMPK phosphorylation contributes to the beneficial effects of Lactobacillus rhamnosus GG supernatant on chronic-alcohol-induced fatty liver disease. J Nutr Biochem. 2015; 26(4):337-44. PMC: 6679353. DOI: 10.1016/j.jnutbio.2014.10.016. View

Sharma S, Tripathi P . Gut microbiome and type 2 diabetes: where we are and where to go?. J Nutr Biochem. 2018; 63:101-108. DOI: 10.1016/j.jnutbio.2018.10.003. View

Bril F, Lomonaco R, Orsak B, Ortiz-Lopez C, Webb A, Tio F . Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology. 2014; 59(6):2178-87. DOI: 10.1002/hep.26988. View

Pecora F, Persico F, Gismondi P, Fornaroli F, Iuliano S, deAngelis G . Gut Microbiota in Celiac Disease: Is There Any Role for Probiotics?. Front Immunol. 2020; 11:957. PMC: 7243837. DOI: 10.3389/fimmu.2020.00957. View

Bril F, McPhaul M, Kalavalapalli S, Lomonaco R, Barb D, Gray M . Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. J Clin Endocrinol Metab. 2021; 106(11):e4360-e4371. DOI: 10.1210/clinem/dgab417. View

Mokhtari Z, Gibson D, Hekmatdoost A . Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. Adv Nutr. 2017; 8(2):240-252. PMC: 5347097. DOI: 10.3945/an.116.013151. View

Rivera A, Flores Monar G, Islam H, Puttagunta S, Islam R, Kundu S . Ulcerative Colitis-Induced Colorectal Carcinoma: A Deleterious Concatenation. Cureus. 2022; 14(2):e22636. PMC: 8959421. DOI: 10.7759/cureus.22636. View

10.

Leblanc J, Fliss I, Matar C . Induction of a humoral immune response following an Escherichia coli O157:H7 infection with an immunomodulatory peptidic fraction derived from Lactobacillus helveticus-fermented milk. Clin Diagn Lab Immunol. 2004; 11(6):1171-81. PMC: 524790. DOI: 10.1128/CDLI.11.6.1171-1181.2004. View

11.

Perez-Perez A, Sanchez-Jimenez F, Vilarino-Garcia T, Sanchez-Margalet V . Role of Leptin in Inflammation and Vice Versa. Int J Mol Sci. 2020; 21(16). PMC: 7460646. DOI: 10.3390/ijms21165887. View

12.

Toor D, Wsson M, Kumar P, Karthikeyan G, Kaushik N, Goel C . Dysbiosis Disrupts Gut Immune Homeostasis and Promotes Gastric Diseases. Int J Mol Sci. 2019; 20(10). PMC: 6567003. DOI: 10.3390/ijms20102432. View

13.

Davani-Davari D, Negahdaripour M, Karimzadeh I, Seifan M, Mohkam M, Masoumi S . Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications. Foods. 2019; 8(3). PMC: 6463098. DOI: 10.3390/foods8030092. View

14.

Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4):1335-1347. PMC: 10026948. DOI: 10.1097/HEP.0000000000000004. View

15.

Le M, Yeo Y, Li X, Li J, Zou B, Wu Y . 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021; 20(12):2809-2817.e28. DOI: 10.1016/j.cgh.2021.12.002. View

16.

Flores Monar G, Islam H, Puttagunta S, Islam R, Kundu S, Jha S . Association Between Type 1 Diabetes Mellitus and Celiac Disease: Autoimmune Disorders With a Shared Genetic Background. Cureus. 2022; 14(3):e22912. PMC: 8986520. DOI: 10.7759/cureus.22912. View

17.

Singh A, Parida S, Narayan J, Nath P, Padhi P, Pati G . Simple Anthropometric Indices are Useful for Predicting Non-alcoholic Fatty Liver Disease [NAFLD] in Asian Indians. J Clin Exp Hepatol. 2017; 7(4):310-315. PMC: 5715478. DOI: 10.1016/j.jceh.2017.05.005. View

18.

Alshaalan R, Aljiffry M, Al-Busafi S, Metrakos P, Hassanain M . Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis. Saudi J Gastroenterol. 2015; 21(2):64-70. PMC: 4392577. DOI: 10.4103/1319-3767.153812. View

19.

Mansour-Ghanaei R, Mansour-Ghanaei F, Naghipour M, Joukar F . Biochemical markers and lipid profile in nonalcoholic fatty liver disease patients in the PERSIAN Guilan cohort study (PGCS), Iran. J Family Med Prim Care. 2019; 8(3):923-928. PMC: 6482810. DOI: 10.4103/jfmpc.jfmpc_243_18. View

20.

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View